Aimmune Therapeutics is dedicated to developing innovative pharmaceutical therapies aimed at treating, preventing, and managing serious food, gastrointestinal (GI), and metabolic-related diseases. The company employs a range of advanced modalities, including biologics and immunotherapy, particularly for allergic conditions. This approach is crucial given the rising global prevalence of allergic diseases, which affect a significant portion of the population. Aimmune's focus extends to various therapeutic areas, such as Exocrine Pancreatic Insufficiency (EPI), Clostridium difficile infections, and Inborn Errors of Metabolism (IEMs), including phenylketonuria (PKU). These conditions often leave patients with limited treatment options, highlighting the importance of Aimmune's mission to provide standardized, science-driven therapies.

The company emphasizes a commitment to advancing science and technology platforms to address the challenges posed by these diseases. By uniting expertise from clinical research and biotechnology, Aimmune aims to create effective treatments that can significantly improve the quality of life for patients and their families. Their work not only targets the medical needs of individuals suffering from food allergies and GI disorders but also seeks to alleviate the broader societal burden associated with these conditions. Through their innovative pipeline, Aimmune Therapeutics is positioned to make a meaningful impact in the field of biopharmaceuticals.

United States

Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.

Aimmune Therapeutics

Company Details